Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20023056 | 0.96 | DPP4 (0.43) | L3MBTL1CES2CES1LMNAALDH1A1 | |
| SCHEMBL20023040 | 0.84 | TDP1 (0.56) | L3MBTL1LMNAALDH1A1DPP4KMT2A | |
| SCHEMBL20023122 | 0.84 | HDAC1 (0.50) | ALDH1A1DPP4KMT2AMAPT | |
| SCHEMBL20023089 | 0.83 | HDAC3 (0.41) | L3MBTL1LMNAALDH1A1DPP4KMT2A | |
| SCHEMBL20023052 | 0.82 | DPP4 (0.46) | L3MBTL1LMNAALDH1A1DPP4KMT2A | |
| SCHEMBL20023057 | 0.82 | HDAC3 (0.43) | L3MBTL1LMNAALDH1A1DPP4KMT2A | |
| SCHEMBL20023067 | 0.81 | MRGPRX4 (0.44) | L3MBTL1LMNAALDH1A1KMT2AMAPT | |
| SCHEMBL20023032 | 0.81 | TDP1 (0.58) | L3MBTL1LMNAALDH1A1DPP4KMT2A | |
| SCHEMBL20023121 | 0.81 | HDAC1 (0.53) | ALDH1A1DPP4KMT2AMAPT | |
| SCHEMBL20023091 | 0.81 | PDE4B (0.63) | L3MBTL1KMT2AMAPTMEN1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | L3MBTL1 3762/4885CES2 469/4885CES1 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.